Antibody-drug conjugates (ADCs) are emerging as a powerful class of targeted therapies, but their development requires balancing the complexities of biologics, highly potent compounds, and specialized manufacturing processes. From conjugation strategy and analytical characterization to scale-up and supply planning, each phase presents unique considerations that can influence a program's path to commercialization.
In this edition of the Outsourced Pharma Capabilities Update (OPCU), discover how industry leaders are approaching the scientific, operational, and manufacturing challenges associated with ADC development. Gain insights into the technologies, development strategies, and CDMO capabilities helping sponsors optimize processes, maintain product quality, and prepare for future growth. Watch the presentations below to learn how organizations are advancing ADC programs from early development through commercial readiness.
Recent Sessions Available On-Demand
Nanoparticles & Solid Dose Formulation – September 2026
Cell Line Development – August 2026
Upcoming OPCU Topics & Times
Solving Solubility & Bioavailability Challenges | 11/10/2026, AM Session
Enabling ADC Success | 12/1/2026, AM Session
Mastering Aseptic Fill/Finish | 12/1/2026, PM Session
Access more on-demand OPCU recordings and upcoming sessions here.
